

CERTIFICATE OF ANALYSIS

PT-141 (Bremelanotide) - 10 mg


Synthetic cyclic heptapeptide melanocortin analogue - lyophilised

Material	PT-141 (Bremelanotide)	Client	novumpeptides.com	Received	2026-08-01 at 2-8 C
Batch / lot	PEP-37-TNE	Label claim	10 mg	Analysed	2026-08-02 to 2026-08-03

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	Conforms	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	99.38%	>= 99.00%	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	0.18%	<= 0.50%	MA-UHPLC-031 / UV 214	Pass
Total related substances	0.62%	<= 1.00%	MA-UHPLC-031 / UV 214	Pass
PT-141 (Bremelanotide) per vial	9.99 mg	9.00-11.00 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	3.70%	<= 8.00%	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	145 ppm	<= 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	0.10%	<= 1.00%	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record MN5ATNE-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

deletion sequence	0.18%
insertion sequence	0.14%
diastereomeric variant	0.10%
N-terminal variant	0.07%
C-terminal variant	0.06%
unresolved peaks	0.07%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Identity and quality attributes met the stated criteria. Mean PT-141 (Bremelanotide) content was 9.99 mg/vial and chromatographic purity was 99.38%.

Identity was established by LC-HRMS against a qualified reference; content and related substances were assessed independently.

Analytical review

Ines Abadi I.Abadi

Quality review

Marcus Oyelaran

Approval date: 2026-08-04 M.Oyelaran

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.